Preventive and therapeutic role of traditional Chinese herbal medicine in hepatocellular carcinoma  by Ting, Chin-Tsung et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 78 (2015) 139e144
www.jcma-online.comReview Article
Preventive and therapeutic role of traditional Chinese herbal medicine in
hepatocellular carcinoma
Chin-Tsung Ting a,b, Wan-Chun Li c,d,e, Chang-Yi Chen c,d, Tung-Hu Tsai b,e,*
a Division of Gastrointestinal Surgery, Department of Surgery, Taipei City Hospital (Renai Branch), Taipei, Taiwan, ROC
b Institute of Traditional Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC
c Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan, ROC
d Department of Dentistry, School of Dentistry, National Yang-Ming University, Taipei, Taiwan, ROC
e Department of Education and Research, Taipei City Hospital, Taipei, Taiwan, ROC
Received March 12, 2014; accepted July 28, 2014AbstractHepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. The clinical management of HCC remains a sub-
stantial challenge. Although surgical resection of tumor tissues seems promising, a high recurrence and/or metastasis rate accounting for disease-
related death has led to an urgent need for improved postsurgical preventive/therapeutic clinical intervention. Developing advanced target-
therapy agents such as sorafenib appears to be the only effective clinical intervention for patients with HCC to date, but only limited trials
have been conducted in this regard. Because of their enhanced preventive/therapeutic effects, traditional Chinese herbal medicine (CHM)-
derived compounds are considered suitable agents for HCC treatment. The CHM-derived compounds also possess multilevel, multitarget, and
coordinated intervention effects, making them ideal candidates for inhibition of tumor progression and HCC metastasis. This article reviews the
anticancer activity of various CHMs with the hope of providing a better understanding of how to best use CHM for HCC treatment.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide and ranks as the second
leading cause of cancer-related death in Taiwan. In a clinical
setting, the current major curative therapies such as liver
transplantation, surgical resection, and local ablation offer
only limited options for HCC treatment.1 More than 70% of
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Assreceiving “curative therapies” due to the presence of tumor
extension or detection of underlying liver disease such as
cirrhosis or both.2 Moreover, despite these curative therapies,
the recurrence rate of HCC remains high. To improve the
therapeutic outcome, many adjuvant treatment methods such
as transarterial chemoembolization (TACE), radiotherapy,
immunotherapy, chemotherapy, and other systemic treat-
ments have been used, with frequently dismal results.3
Although the recently developed advanced target-therapy
agents such as sorafenib (a vascular endothelial growth
factor receptor and tyrosine kinase inhibitor) have been used
in clinical settings to prolong survival in patients with
advanced HCC, their therapeutic potential to date is limited
due to their high cost and the significant side effects asso-
ciated with their use.4 Much effort has been put into iden-
tifying alternative therapies to increase the efficacy ofociation. All rights reserved.
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improve quality of life and survival of patients. Based on
recent reports, traditional Chinese herbal medicine (CHM)
seems to be emerging as an intriguing and viable choice
because of its multilevel, multitarget, and coordinated
intervention effects against HCC. The extensive application
of phytochemical and molecular biological approaches in
many CHM-derived compounds has shown great potential in
developing anti-HCC natural products.5 In this article, we
comprehensively discuss the current state of understanding
and the underlying pharmacological mechanisms of different
CHMs that are used as a chemopreventive/chemotherapeutic
agent for HCC treatment.
2. Molecular pathogenesis of HCC
HCC is a multifactorial disease caused by viral hepatitis
infection, alcohol consumption, tobacco use, and exposure to
aflatoxin and certain other chemical agents.6 Numerous
studies have shown that development of HCC is a multistep
process.7 The disease is initiated by mutation in various
oncogenic genes. It has been found that hepatitis B virus-
associated HCC genes are involved in various aspects of
physiological regulation including protein synthesis [ribo-
somal protein S5 (RPS5)], cytoskeletal organization [keratin-8
(KRT8)], apoptosis [Fas-associated protein with death domain-
like apoptosis regulator (CFLAR)], ion transportation (adeno-
sine triphosphate synthase Hþ transporting mitochondrial Fo
complex subunit B1; ATP5F1), signal transduction (mitogen-
activated protein kinase kinase kinase 5 and insulin-like
growth factor binding protein 2), and metastasis (matrix
metallopeptidase-9 or MMP-9).8 Other genes associated with
cell structure [vimentin (vim) and beta-actin (ACTB)],
glycolysis (glyceraldehyde 3-phosphate dehydrogenase), and
cell adhesion (lymphocyte function-associated antigen 3;
CD58) have also been shown to be enriched in hepatitis C
virus-mediated HCC tissues compared with normal tissues.9
Genetic mutations in these genes trigger HCC progression
by activating certain oncogenic pathways such as the
RafeMEKeERK pathway, phosphatidylinositol 3-kinase/Akt/
mammalian target of rapamycin pathway, Wnt/b-catenin
pathway, insulin-like growth factor pathway, hepatocyte
growth factor/c-MET pathway, and growth factor-regulated
angiogenic signaling.8 In addition to the intrinsic genetic/
signaling regulation, a growing body of evidence has also
suggested that hosteviral interactions, including immune
response-induced hepatocyte necrosis and inflammation-
mediated regeneration, might also contribute to hep-
atocarcinogenesis.10 In brief, from a pathological point of
view, the following two main mechanisms prevail during
hepatocarcinogenesis: (1) cirrhosis associated with hepatic
regeneration following tissue damage caused by hepatitis
infection, toxins (e.g., alcohol or aflatoxin), or metabolic in-
fluences; and (2) mutations occurring in single or multiple
oncogenes or tumor-suppressor genes. Although both mecha-
nisms have been linked with modulations in the numbers of
cellular signaling pathways, it remains a substantial challengeto clarify how these two pathogenic mechanisms act syner-
gistically for HCC development.8
3. Anti-HCC effects of traditional CHM
In contrast to the trials undertaken and procedures per-
formed to combat other highly prevalent cancers, such as lung,
breast, and colorectal cancers, relatively fewer medical in-
terventions and trials are available with regard to HCC. This
has led to an urgent need to develop new, active, and well-
tolerated treatments to improve survival in patients with
advanced HCC and to increase enduring remission after
curative treatment.11 Although further work would be required
to elucidate the detailed mechanisms behind CHM-mediated
anticancer effects, evidence accumulated in the past several
decades confirms the preventive and therapeutic effects of
using CHM against HCC. In addition, the cellular and mo-
lecular basis of anti-HCC activity of different CHMs has also
gradually been uncovered.3.1. Scutellaria baicalensisBaicalein, a flavonoid present in the herbal medicine sho-
saiko-to (i.e., TJ-9; also known as xiao-chai-hu-tang in Chi-
nese), is a widely used CHM for anti-inflammatory and anti-
cancer therapies. Baicalein is reported to inhibit the activity of
topoisomerase II and suppress the proliferation of HCC cell
lines by G2/M phase cell cycle arrest in vitro.
12 Moreover,
treatment with Scutellaria baicalensis decreases the expression
of p53, ETS1, Cdc25B, p63, epidermal growth factor receptor,
ERK1/2, X-linked inhibitor of apoptosis protein, hypoxia-
inducible factor 2a, and Cdc25C and upregulates the activity
of cyclin E in a dose-dependent manner, suggesting that S.
baicalensis exerts anti-HCC effects on broad cell-signaling
networks, thereby leading to a collective inhibition of cell pro-
liferation.13 In addition, baicalein decreased MMP-2, MMP-9,
and urokinase-type plasminogen activator expression as well as
inhibiting the activity of the ERK signaling pathway, implying
that baicalein could possibly regulate HCC invasion and
metastasis.14 The anti-HCC activity of baicalein was also
described in vivo in a recent study in which mice treated with
baicalein extract showed a significantly decreased growth of
HepG2 xenografts compared with the control groups.153.2. BerberineCoptis chinensis and its major constituent berberine are
frequently used in treating diabetes mellitus, diarrhea, acute
enteritis, dysentery, delirium due to high fever, leukemia, and
otitis media. Recent experiments have found that both C.
chinensis and berberine exhibited anticancer potential by
inhibiting cell proliferation, induction of apoptosis, and G2/M
cell cycle arrest. At the molecular level, C. chinensis/berberine
induced an anticancer effect through various types of molec-
ular regulation, including inhibition of antiapoptotic protein
bcl-2, activation of caspase cascade as well as the activation of
Egr1-NAG-1 (nonsteroidal anti-inflammatory drug-activated
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indicated that a newly developed long-lasting polyethylene
glycol-based liposomal berberine exhibited anti-HCC poten-
tial in vitro and in vivo, further suggesting its chemopreventive
effect in hepatocarcinogensis.173.3. Chrysanthemum indicum Linn.Chrysanthemum indicum Linn. (Asteraceae) is a common
CHM that has traditionally been used for the treatment of
inflammation, hypertension, and neoplastic diseases in China.
A recent study demonstrated that C. indicum Linn. extracts
exhibit anti-HCC effects by attenuation of mitogenic signaling
mitogen-activated protein kinase/ERK1/2 through the b2-
adrenergic receptor on isoproterenol-induced growth in
HepG2 and MHCC97H cells.183.4. Tanshinone IIADanshen (Salvia miltiorrhizaRadix) has widely been used in
traditional CHM to treat cardiovascular and hepatic diseases.
Tanshinone IIA (Tan-IIA; C19H18O3) was extracted from S.
miltiorrhiza Radix and its antioxidant, anti-inflammatory, and
antitumor activities have been well documented in many human
cancer cells. The anticancer effect of Tan-IIA was detected
mainly through growth inhibition and induced apoptosis in
human HCC.19e21 It has been shown that Tan-IIA-mediated
apoptosis activation and proliferation inhibition might occur
through upregulated expression of stress-mediated proapoptotic
proteins calreticulin, caspase-12, and GADD153.22 More
recently, several other in vivo studies further confirmed that Tan-
IIA inhibited the growth of J5 and H22 hepatocellular xeno-
grafts, possibly by modulating the activity of proapoptotic/
antiapoptotic proteins.23,24 In addition to regulating cancer cell
viability, Tan-IIA was also believed to suppress cellular meta-
static activity by reducing the activity ofMMP-2,MMP-9,25 and
modulating the hypoxia-inducible factor 1a-mediated epi-
thelialemesenchymal transition process.263.5. Solanum nigrum L.Solanum nigrum L., a herbal plant indigenous to Southeast
Asia, is a routinely administered oriental medicine. A previous
study has shown that ripe fruits of S. nigrum L. induced
growth inhibition and apoptosis in breast cancer cells.27 A
number of studies have shown that S. nigrum L. polyphenolic
extract (SNPE) induces elevated cell cycle arrest, increased
autophagy, and upregulated apoptosis in HCC cells.28,29 At the
molecular level, SNPE attenuated cell cycle regulators
Cdc25A, Cdc25B, and Cdc25C; apoptosis mediators caspase-
3, caspase-8, and caspase-9; as well as Bcl-2 family proteins
both in vitro and in vivo.303.6. TetrandrineTetrandrine is a bisbenzylisoquinoline alkaloid isolated from
the roots of Radix Stephaniae tetrandrae S. Moore. Radix S.tetrandrae S.Moore is an ancient ingredient of traditional CHM
and is broadly used in China to treat patients with arthritis, hy-
pertension, inflammation, and even silicosis.31 It was shown that
tetrandrine achieves symptom relief through a pharmacological
mechanism in which tetrandrine blocks Ca2＋channels; in
addition, tetrandrine has immunosuppressive property, free-
radical scavenging effects, and antiproliferative features.32
Moreover, it was reported that administration of tetrandrine
led to G1 phase cell cycle arrest and induced apoptosis in many
cancer cells through the inhibition of pro-proliferative ERK
signaling.33,34 The treatment of liver cancer cells with tetran-
drine altered their morphology, induced chromatin fragmenta-
tion, and stimulated caspase activity. Interestingly, tetrandrine
administration also induced intracellular accumulation of
reactive oxygen species (ROS), whereas ROS scavengers, such
as N-acetyl-l-cysteine and glutathione (GSH), completely
abolished tetrandrine-induced apoptosis suggesting that ROS
generation plays an important role in tetrandrine-mediated
apoptosis. Furthermore, downstream Akt-associated apoptotic
activity was upregulated in response to ROS generation, which
indicates a possible molecular cascade for tetrandrine-mediated
anticancer effect. Taken together, these findings suggest that
tetrandrine could serve as an ROS/Akt regulator and could be
implicated for HCC treatment.35 Furthermore, tetrandrine also
exhibited an anti-HCC effect in vivo. It has been shown that
paclitaxel/tetrandrine co-loaded nanoparticles could efficiently
repress tumor growth,36 whereas accumulated ROS and
increased autophagy were detected in Huh7 xenografts that lead
to decreased tumor volume in response to tetrandrine
treatment.373.7. AndrographolideAndrographis paniculata has been a CHM for the treatment
of respiratory infection, fever, bacterial dysentery, and diar-
rhea in many Asian countries for centuries. Andrographolide
(ANDRO), an active compound isolated from A. paniculata, is
known to possess various physiological regulatory character-
istics such as anti-inflammatory, antibacterial, and hep-
atoprotection. ANDRO inhibited the growth of hepatoma cells
by activation of c-Jun NH2-terminal kinase (JNK) and reduc-
tion of GSH levels.38,39 ANDRO also caused ROS-stimulated
cycle arrest leading to the hypothesized crosstalk between
JNK activation, cellular GSH homeostasis, and cytotoxicity in
hepatoma cells.40,413.8. GambogeGamboge is also a traditional CHM used for hundreds of
years. Its major compounds gambogic acid (GA) and gam-
bogenic acid are isolated from Garcinia hanburyi, and have
been shown to have antiproliferative effects in HCC cell lines.
In addition, it was also found that 1,3,6,7-
tetrahydroxyxanthone (TTA), a xanthone derivative from
Goodyera oblongifolia, could be a potent apoptosis inducer in
HCC cells. Previous studies have demonstrated that TTA
suppressed HCC through upregulated gene expression of p16
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made evident by the decreased size of SMMC-7721 xeno-
transplanted tumor in mice, possibly through the inhibition of
telomerase activity.433.9. Cornus officinalisCornus officinalis Sieb. et Zucc. (Cornaceae) is another
widely used CHM, with antineoplasm and anti-inflammation
activities. Extracts of C. officinalis Sieb. et Zucc. could also
downregulate lipid peroxidation resulting in hep-
atoprotection.44 Regarding its anticancer effect, previous
studies found that extracts of C. officinalis Sieb. et Zucc.
exhibited a dose-dependent suppression of mutant p53 and
Ras-mediated oncogenic progression and inhibited oxidative
stress by scavenging free radicals against HCC cells, making
C. officinalis Sieb. et Zucc. an effective chemopreventive
agent against HCC.443.10. CurcuminCurcumin is one of the major phenolic agents in the spice
turmeric (Curcuma longa). There are three majorTable 1
Anti-HCC effects of CHM.
CHM/compounds For initiation For survival/prolifer
Scutellaria baicalensis G2/M phase arrest
Y topoisomerase II
(in vitro)12
Y p53, ETS1, Cdc2
XIAP, HIF-2a, and
[ Cyclin E (in vitro
Y HepG2 xenograft
Berberine/Coptis chinensis G2/M phase arrest
(in vitro)15
Y Bcl-2;
[ Activation of pro
and NAG-1 protein
Y HepG2 xenograft
Chrysanthemum indicum Linn.
Tanshinone IIA (Salvia
miltiorrhiza Radix)
G2/M phase arrest
(in vitro)19e21
Y Bcl-2
[ p53, p21, Bax, ca
GADD153 (in vitro
Y J5/H22 xenograft
Solanum nigrum L. G2/M phase arrest
(in vitro)27e29
Y Cdc25A, Cdc25B
Y HepG2 xenograft
Tetrandrine [ ROS;Y Akt pathw
[ ROS; [ Autopha
Y Huh7 xenograft t
Andrographolide [ ROS and JNK
Y Glutathione level
Gamboge [ p16; 14-3-3s gen
Y SMMC-7721 xen
Y Telomerase activi
Cornus officinalis Sieb. et Zucc. Y p53 and Ras mut
Curcumin G2/M phase arrest
(in vitro)47
[ Telomerase activi
nuclear DNA damag
[ 8-OHdG; [ ROS
Resveratrol G1/S phase arrest
(in vitro)56
Y Cyclin D1, p38, a
[ p53, p21, caspase
DNA fragmentation
8-OHdG ¼ 8-hydroxy-20-deoxyguanosine; CHM ¼ Chinese herbal medicine; EG
EMT ¼ epithelialemesenchymal transition; ERK ¼ extracellular signal-regulated
factor 2a; JNK ¼ c-Jun NH2-terminal kinase; MAPK ¼ mitogen-activated pro
ROS ¼ reactive oxygen species; uPA ¼ urokinase-type plasminogen activator;
apoptosis protein.curcuminoids that constitute curcumin, which are as follows:
curcumin (curcumin I, 75%), demethoxycurcumin (curcumin
II, 20%), and bisdemethoxycurcumin (curcumin III, 5%).45
Although curcumin is not a traditional CHM, it has been
considered as a chemoprevention agent that could suppress
neoplasias, inflammation, viral infection, oxidative stress, and
human immunodeficiency virus-mediated pathology for cen-
turies.46 A number of studies have demonstrated that curcumin
could induce G2/M phase cell cycle arrest,
47 inhibit prolifer-
ation,48 induce apoptosis,49 and suppress angiogenesis and
metastasis50 in different HCC cell lines. Furthermore, using
in vivo models, the anticancer activity of curcumin was also
documented indicating that curcumin could effectively reduce
cancer cell multiplicity,51 attenuate tumor growth,52 decrease
telomerase activity, prevent tumor angiogenesis, and inhibit
intrahepatic metastasis.533.11. ResveratrolResveratrol (trans-3,5,40-trihydroxystilbene) is a natural
antioxidant polyphenol compound that can be found in a wide
variety plants including grapes, peanuts, and berries, and could
also be isolated from the dried roots of CHM Polygonumation For angiogenesis/metastasis
5B, p63, EGFR, ERK1/2,
Cdc25C;
)13
tumor size (in vivo)15
Y ERK signaling
Y MMP-2, MMP-9, and uPA (in vitro)14
caspase-3 and procaspase-9,
(in vitro)15
tumor size (in vivo)17
Y MAPK/ERK1/2 signaling (in vitro)18
lreticulin, caspase 12, and
)19,21,22
tumor size (in vivo)23,24
Y EGF and EGFR (in vitro)20
Y MMP-2, MMP-9
Y HIF-1a-mediated EMT (in vivo)25,26
, Cdc25C;Y Bcl-2 (in vitro)30
tumor size (in vivo)30
ay (in vitro)35
gy
umor size (in vivo)37
(in vitro)39e41
e expression (in vitro)42
ograft tumor growth
ty (in vivo)43
ation (in vitro)44
ty; mitochondrial and
e (in vitro)48
(in vitro)50
Y HIF-1a and VEGF (in vivo)51,53
Y MMP-9 (in vivo)52
nd Akt;
2,3, 8, and 10, and
(in vitro)57
Y HIF-1a, VEGF, JNK1/2, SP-1
DNA, NF-кB, VEGF, and uPA (in vitro)58
F ¼ epidermal growth factor; EGFR ¼ epidermal growth factor receptor;
kinase; HIF-1a ¼ hypoxia-inducible factor 1a; HIF-2a ¼ hypoxia-inducible
tein kinase; MMP ¼ matrix metallopeptidase; NF-kB ¼ nuclear factor-kB;
VEGF ¼ vascular endothelial growth factor; XIAP ¼ X-linked inhibitor of
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resveratrol can prevent or slow the progression of a wide va-
riety of tumors including HCC.55 At the molecular level,
resveratrol inhibited cell growth through G1 phase cell cycle
arrest and increased the expression of inducible nitric oxide
synthase (NOS) and endothelial NOS.56 Resveratrol was also
suggested to induce apoptosis by the activation of caspase-2,
-8, and -10.57 In addition, treatment with resveratrol signifi-
cantly inhibited cell migration and invasion leading to sup-
pression of metastasis.58
In conclusion an overview of anticancer effects of
the aforementioned traditional CHM is summarized
in Table 1.12e15,17e30,35,37,39e44,47,48,50e53,56e58 While CHMs
have been routinely applied in Eastern Asia and are increas-
ingly common worldwide, if and when its many antitumor
aspects are fully evaluated, CHM could become an ideal new
alternative “medication” against HCC considering its low
toxicity and high activity.59e61 With regard to the therapeutic
aspects, CHM has been proposed to be active against HCC
initiation, survival, proliferation, angiogenesis, and metastasis
using various in vitro and in vivo models. Furthermore, CHM
could also synergistically enhance HCC inhibition and im-
mune function as well as reduce the toxic effects when com-
bined with radiotherapy, chemotherapy, and TACE.62 Taken
together, although it is clear that many CHMs possess excel-
lent anticancer activity, evaluating the clinical applications of
CHM using randomized, controlled clinical cohorts of liver
cancer patients is still required.
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